查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1769601

医药品中间体CDMO的全球市场:各用途，中间体类别，医药品类别，各地区 - 2035年前的预测分析

Global Pharmaceutical Intermediate CDMO Market Research Report by Application, by Type of Intermediate, by Drug Type, and by Region Forecast Analysis till 2035
出版日期: | 出版商: Market Research Future | 英文 146 Pages | 订单完成后即时交付

价格

2024年，全球医药中间体CDMO市场规模为1,617.989亿美元。预计2024年至2035年，该市场规模将达3,467.443亿美元，复合年增长率为7.4%。

受多种因素影响，全球医药中间体CDMO市场正快速扩张。製药公司为提高效率和减轻营运负担，越来越多地采用外包模式。对仿製药和生物相似药的需求日益增长，尤其是在中低收入国家，是主要的成长因素。此外，中间体合成技术的进步和新药製剂的复杂性，促使企业寻求专业的CDMO支援。新兴国家医疗基础设施的建设也促进了市场的发展。

另一方面，严格的监管合规要求和漫长的审批週期往往会阻碍进展。高昂的资本和营运成本、智慧财产权相关风险以及持续的供应链中断都是显着的障碍。缺乏先进的化学专业知识也是一个课题。儘管存在这些问题，但透过与生物技术公司建立策略合作伙伴关係，以及对客製化、患者专用药物解决方案日益增长的需求，该市场仍然存在着广阔的机会。

产业区隔

按应用领域，全球市场细分为肿瘤学、心血管疾病、中枢神经系统和神经系统疾病以及传染病。

依药物类型，全球医药中间体 CDMO 市场包括仿製药和品牌药。

全球医药中间体 CDMO 市场按中间体类型细分，包括活性药物成分 (API)、生物中间体、辅料和添加剂以及核苷酸中间体。

依地区划分，全球医药中间体CDMO市场分为北美、欧洲、南美、中东和非洲、亚太地区。

区域分析

北美医药中间体CDMO市场规模最大、发展最成熟，其中美国凭藉其高科技基础设施、巨额研发投入以及FDA严格的品质监管而处于领先地位。加拿大生物製药产业的成长进一步增强了该地区的实力。

欧洲既迎合国内巨头，也迎合全球企业，注重法规合规性、复杂合成的创新以及符合循环经济原则的可持续生产方法。

以中国和印度为首的亚太地区是成长最快的地区。经济高效的製造、大规模的设施和一体化的供应链使具有竞争力的中间体生产成为可能。

拉丁美洲各国面临不同的监管框架，但正在透过区域合作努力实现统一的标准。具有竞争力的劳动力成本和靠近美国的地理位置是其优势，但基础设施的限制在一定程度上阻碍了其成长。

在中东和非洲，CDMO主要透过生产仿製药和基本药物的中间体来服务当地和邻近市场。该地区位于亚洲和欧洲之间，预计将成为医药物流和中间体供应的潜在枢纽。随着全球供应链的发展，中东和非洲地区作为跨洲製造桥樑的角色可能会更加突出。

主要参与者

赛默飞世尔科技、Raghava Life Sciences Pvt LTD.、Cambrex Corporation、Actylis、Chiracon GmbH、Codexis, Inc.、Arkema S.A.、龙沙集团、康泰伦特和浙江九洲药业股份有限公司是全球医药中间体CDMOMO市场的主要竞争对手。

本报告调查了全球医药中间体CDMO市场，并提供了市场概况、按应用、中间体类型、药品类型和地区划分的趋势以及参与市场的公司概况。

目录

第1章 摘要整理

第2章 市场简介

第3章 调查手法

第4章 市场动态

  • 简介
  • 促进因素
    • 药厂外包业务不断增加
    • 仿製药和生物相似药需求不断成长
    • 中间体合成技术的进步
    • 药物分子日益复杂
    • 向新兴市场扩张
  • 阻碍因素
    • 严格的监管合规和复杂的审批流程
    • 高昂的营运和资本支出成本
    • 智慧财产权 (IP) 风险与保密问题
    • 供应链中断与原料材料短缺
    • 先进技术与利基化学专业知识有限
  • 机遇
    • 与生技公司建立策略伙伴关係
    • 专注于个人化医疗解决方案
  • COVID的影响分析-

第5章 市场要素分析

  • 供应链分析
    • 原料采购
    • 调查，开发，流程最佳化
    • 製造和品管
    • 包装，保管，物流，发送，对客户的发送
  • 波特的五力分析

第6章 全球医药品中间体CDMO市场(中间体类别)

  • 简介
  • 原料药(API)
  • 赋形剂及添加物

第7章 全球医药品中间体CDMO市场(医药品类别)

  • 简介
  • 学名药
  • 品牌医药品

第8章 全球医药品中间体CDMO市场(各用途)

  • 简介
  • 肿瘤学
  • 心血管疾病
  • 中枢神经系统及神经疾病
  • 感染疾病
  • 其他

第9章 全球医药品中间体CDMO市场(各地区)

  • 世界
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他
  • 亚太地区
    • 中国
    • 韩国
    • 印度
    • 日本
    • 印尼
    • 马来西亚
    • 泰国
    • 其他
  • 南美
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他
  • 中东·非洲
    • GCC各国
    • 南非
    • 其他

第10章 竞争情形

  • 简介
  • 市场占有率分析，2024年
  • 竞争仪表板

第11章 企业简介

  • RAGHAVA LIFE SCIENCES PVT LTD
  • ACTYLIS
  • CHIRACON GMBH
  • CODEXIS, INC.
  • ARKEMA S.A.
  • LONZA GROUP AG
  • THERMO FISHER SCIENTIFIC(PATHEON)
  • CAMBREX CORPORATION
  • CATALENT, INC.
  • ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD

Global Pharmaceutical Intermediate CDMO Market Research Report by Application (Oncology, Cardiovascular Diseases, CNS & Neurological Disorders, Infectious Diseases), by Type of Intermediate [Active Pharmaceutical Ingredients (APIs), Excipients and Additives, Biologics Intermediates, Nucleotide Intermediates], by Drug Type (Generic Drugs, Branded Drugs), and by Region (North America, Europe, South America, Middle East and Africa, and Asia Pacific) Forecast Analysis till 2035

Industry Overview

In 2024, global pharmaceutical intermediate CDMO market was valued at USD 161,798.9 million. It is projected to increase at a compound annual growth rate (CAGR) of 7.4% from 2024 to 2035, reaching USD 346,744.3 million.

The global market for Pharmaceutical Intermediate CDMOs is expanding rapidly due to various contributing factors. Outsourcing by pharmaceutical firms is on the rise as they aim to enhance efficiency and reduce operational burdens. The increasing need for generic drugs and biosimilars, especially in low- and middle-income countries, is a major growth driver. Additionally, advancements in intermediate synthesis technologies and the complex nature of new drug formulations are pushing companies toward specialized CDMO support. The growth of healthcare infrastructure in emerging economies is also enhancing the market landscape.

On the flip side, stringent regulatory compliance requirements and lengthy approval timelines often hamper progress. High capital and operational expenses, intellectual property-related risks, and ongoing supply chain disruptions present notable barriers. A shortage of expertise in advanced chemistry remains another challenge. Despite these issues, the market holds promising opportunities through strategic alliances with biotechnology companies and the increasing demand for tailored, patient-specific medicine solutions.

Industry Segmentations

In terms of application types, the global market is divided into oncology, cardiovascular diseases, CNS and neurological disorders, and infectious disease.

Based on the drug type, global pharmaceutical intermediate CDMO market comprises generic drugs, branded drug.

Global Pharmaceutical intermediate CDMO market has been categorized by type of intermediate, includes active pharmaceutical ingredients (APIS), biologics intermediates, excipients and additives, nucleotide intermediates.

Regionally, global pharmaceutical intermediate CDMO market divided into North America, Europe, South America, Middle East and Africa, and Asia Pacific.

Regional Analysis

The North American market for pharmaceutical intermediate CDMOs is the largest and most sophisticated, with the U.S. leading due to high-tech infrastructure, heavy R&D investments, and FDA-enforced quality regulations. Canada's rising biopharmaceutical industry further supports regional strength.

Europe caters to both domestic powerhouses and global players, emphasizing regulatory compliance, innovation in complex syntheses, and sustainable production practices aligned with circular economy principles.

Asia Pacific, spearheaded by China and India, is witnessing the fastest growth. Cost-effective manufacturing, large-scale facilities, and integrated supply chains enable competitive production of intermediates.

Latin America, while facing diverse regulatory frameworks across countries, is working toward unified standards through regional cooperation. Competitive labor costs and proximity to the U.S. are advantageous, though growth is somewhat hindered by infrastructure constraints.

In the Middle East and Africa, CDMOs largely serve local and neighboring markets by producing intermediates for generic medicines and essential drugs. The region's favorable location between Asia and Europe positions it as a potential hub in pharmaceutical logistics and intermediate supply. As global supply chains evolve, MEA's role may become more pronounced in bridging manufacturing efforts across continents.

Key Players

Thermo Fisher Scientific, Raghava Life Sciences Pvt LTD., Cambrex Corporation, Actylis, Chiracon GmbH, Codexis, Inc., Arkema S.A., Lonza Group AG, Catalent, Inc., Zhejiang Jiuzhou Pharmaceutical Co Ltd are the key competitors of the global pharmaceutical intermediate CDMO market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

  • 1.1 MARKET OVERVIEW:
  • 1.2 MARKET SEGMENTATION
  • 1.3 COMPETITIVE LANDSCAPE
  • 1.4 FUTURE OUTLOOK

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

  • 3.1 OVERVIEW
  • 3.2 DATA FLOW
    • 3.2.1 Data Mining Process
  • 3.3 PURCHASED DATABASE:
  • 3.4 SECONDARY SOURCES:
    • 3.4.1 Secondary Research Data Flow:
  • 3.5 PRIMARY RESEARCH:
    • 3.5.1 Primary Research DATA FLOW:
    • 3.5.2 Primary Research: Number of Interviews conducted
    • 3.5.3 Primary Research: Regional Coverage
  • 3.6 APPROACHES FOR MARKET END USER ESTIMATION:
    • 3.6.1 Revenue Analysis Approach
    • 3.6.2 Data forecasting
    • 3.6.3 Data Forecasting Technique
  • 3.7 DATA MODELING
    • 3.7.1 microeconomic factor analysis:
    • 3.7.2 Data modeling:
  • 3.8 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

  • 4.1 INTRODUCTION
  • 4.2 DRIVERS
    • 4.2.1 Increasing Outsourcing by Pharmaceutical Companies
    • 4.2.2 Rising Demand for Generic Drugs and Biosimilars
    • 4.2.3 Technological Advancements in Intermediate Synthesis
    • 4.2.4 Growing Complexity of Drug Molecules
    • 4.2.5 Expansion in Emerging Markets
  • 4.3 RESTRAINTS
    • 4.3.1 Stringent Regulatory Compliance and Complex Approval Processes
    • 4.3.2 High Operational and Capital Expenditure Costs
    • 4.3.3 Property (IP) Risks and Confidentiality Concerns
    • 4.3.4 Supply Chain Disruptions and Raw Material Shortages
    • 4.3.5 Limited Expertise in Advanced Technologies and Niche Chemistry
  • 4.4 OPPORTUNITY
    • 4.4.1 Strategic Partnerships with Biotech Firms
    • 4.4.2 Focus on Personalized Medicine Solutions
  • 4.5 IMPACT ANALYSIS OF COVID - 19

5 MARKET FACTOR ANALYSIS

  • 5.1 SUPPLY CHAIN ANALYSIS
    • 5.1.1 Raw Material Sourcing & Procurement
    • 5.1.2 Research, Development, & Process Optimization
    • 5.1.3 Manufacturing & Quality Control
    • 5.1.4 Packaging, Storage, & Logistics & Distribution & Customer Delivery
  • 5.2 PORTER'S FIVE FORCES MODEL
    • 5.2.1 Threat of New Entrants (Low to Moderate)
    • 5.2.2 Bargaining Power of Suppliers (Moderate)
    • 5.2.3 Threat of Substitutes (Low to Moderate)
    • 5.2.4 Bargaining Power of Buyers (High)
    • 5.2.5 Intensity of Rivalry (High)

6 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE

  • 6.1 INTRODUCTION
  • 6.2 ACTIVE PHARMACEUTICAL INGREDIENTS (APIS)
  • 6.3 EXCIPIENTS & ADDITIVES

7 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE

  • 7.1 INTRODUCTION
  • 7.2 GENERIC DRUGS
  • 7.3 BRANDED DRUGS

8 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
  • 8.2 ONCOLOGY
  • 8.3 CARDIOVASCULAR DISEASES
  • 8.4 CNS & NEUROLOGICAL DISORDERS
  • 8.5 INFECTIOUS DISEASES
  • 8.6 OTHERS

9 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY REGION

  • 9.1 GLOBAL
  • 9.2 NORTH AMERICA
    • 9.2.1 USA
    • 9.2.2 CANADA
  • 9.3 EUROPE
    • 9.3.1 united kingdom
    • 9.3.2 germany
    • 9.3.3 france
    • 9.3.4 italy
    • 9.3.5 spain
    • 9.3.6 RUSSIA
    • 9.3.7 rest of europe
  • 9.4 ASIA PACIFIC
    • 9.4.1 china
    • 9.4.2 South Korea
    • 9.4.3 indiA
    • 9.4.4 Japan
    • 9.4.5 indonesia
    • 9.4.6 malaysia
    • 9.4.7 thailand
    • 9.4.8 rest of asia pacific
  • 9.5 SOUTH AMERICA
    • 9.5.1 Mexico
    • 9.5.2 Brazil
    • 9.5.3 argentina
    • 9.5.4 rest of south america
  • 9.6 MIDDEL EAST AND AFRICA
    • 9.6.1 gcc countries
    • 9.6.2 south africa
    • 9.6.3 rest of middle east & africa

10 COMPETITIVE LANDSCAPE

  • 10.1 INTRODUCTION
  • 10.2 MARKET SHARE ANALYSIS, 2024SS
  • 10.3 COMPETITOR DASHBOARD

11 COMPANY PROFILES

  • 11.1 RAGHAVA LIFE SCIENCES PVT LTD
    • 11.1.1 COMPANY OVERVIEW
    • 11.1.2 Key Development
    • 11.1.3 SWOT ANALYSIS
    • 11.1.4 Key Strategy
  • 11.2 ACTYLIS
    • 11.2.1 COMPANY OVERVIEW
    • 11.2.2 PRODUCT OFFERED
    • 11.2.3 Key Development
    • 11.2.4 SWOT ANALYSIS
    • 11.2.5 Key Strategy
  • 11.3 CHIRACON GMBH
    • 11.3.1 COMPANY OVERVIEW
    • 11.3.2 PRODUCT OFFERED
    • 11.3.3 SWOT ANALYSIS
    • 11.3.4 Key Strategy
  • 11.4 CODEXIS, INC.
    • 11.4.1 COMPANY OVERVIEW
    • 11.4.2 PRODUCT OFFERED
    • 11.4.3 Key Development
    • 11.4.4 SWOT ANALYSIS
    • 11.4.5 financial analysis
    • 11.4.6 Key Strategy
  • 11.5 ARKEMA S.A.
    • 11.5.1 COMPANY OVERVIEW
    • 11.5.2 PRODUCT OFFERED
    • 11.5.3 SWOT ANALYSIS
    • 11.5.4 financial analysis
    • 11.5.5 Key Strategy
  • 11.6 LONZA GROUP AG
    • 11.6.1 COMPANY OVERVIEW
    • 11.6.2 PRODUCT OFFERED
    • 11.6.3 Key Development
    • 11.6.4 SWOT ANALYSIS
    • 11.6.5 financial analysis
    • 11.6.6 Key Strategy
  • 11.7 THERMO FISHER SCIENTIFIC (PATHEON)
    • 11.7.1 COMPANY OVERVIEW
    • 11.7.2 PRODUCT OFFERED
    • 11.7.3 Key Development
    • 11.7.4 SWOT ANALYSIS
    • 11.7.5 financial analysis
    • 11.7.6 Key Strategy
  • 11.8 CAMBREX CORPORATION
    • 11.8.1 COMPANY OVERVIEW
    • 11.8.2 PRODUCT OFFERED
    • 11.8.3 Key Development
    • 11.8.4 SWOT ANALYSIS
    • 11.8.5 Key Strategy
  • 11.9 CATALENT, INC.
    • 11.9.1 COMPANY OVERVIEW
    • 11.9.2 PRODUCT OFFERED
    • 11.9.3 Key Development
    • 11.9.4 SWOT ANALYSIS
    • 11.9.5 financial analysis
    • 11.9.6 Key Strategy
  • 11.10 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD
    • 11.10.1 COMPANY OVERVIEW
    • 11.10.2 PRODUCT OFFERED
    • 11.10.3 Key Development
    • 11.10.4 SWOT ANALYSIS
    • 11.10.5 financial analysis
    • 11.10.6 Key Strategy

LIST OF TABLES

  • TABLE 1 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 2 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 3 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 4 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY REGION, 2019-2035 (USD MILLION)
  • TABLE 5 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
  • TABLE 6 NORTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 7 NORTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 8 NORTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 9 USA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 10 USA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 11 USA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 12 CANADA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 13 CANADA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 14 CANADA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 15 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
  • TABLE 16 EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 17 EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 18 EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 19 UK PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 20 UK PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 21 UK PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 22 GERMANY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 23 GERMANY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 24 GERMANY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 25 FRANCE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 26 FRANCE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 27 FRANCE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 28 ITALY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 29 ITALY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 30 ITALY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 31 SPAIN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 32 SPAIN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 33 SPAIN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 34 RUSSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 35 RUSSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 36 RUSSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 37 REST OF EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 38 REST OF EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 39 REST OF EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 40 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
  • TABLE 41 ASIA PACIFIC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 42 ASIA PACIFIC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 43 ASIA PACIFIC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 44 CHINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 45 CHINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 46 CHINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 47 SOUTH KOREA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 48 SOUTH KOREA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 49 SOUTH KOREA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 50 INDIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 51 INDIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 52 INDIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 53 JAPAN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 54 JAPAN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 55 JAPAN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 56 INDONESIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 57 INDONESIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 58 INDONESIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 59 MALAYSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 60 MALAYSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 61 MALAYSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 62 THAILAND PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 63 THAILAND PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 64 THAILAND PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 65 REST OF APAC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 66 REST OF APAC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 67 REST OF APAC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 68 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO, BY COUNTRY, 2019-2035 (USD MILLION)
  • TABLE 69 SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 70 SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 71 SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 72 MEXICO PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 73 MEXICO PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 74 MEXICO PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 75 BRAZIL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 76 BRAZIL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 77 BRAZIL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 78 ARGENTINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 79 ARGENTINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 80 ARGENTINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 81 REST OF SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 82 REST OF SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 83 REST OF SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 84 MIDDEL EAST AND AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
  • TABLE 85 MIDDLE EAST & AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 86 MIDDLE EAST & AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 87 MIDDLE EAST & AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 88 GCC COUNTRIES PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 89 GCC COUNTRIES PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 90 GCC COUNTRIES PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 91 SOUTH AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 92 SOUTH AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 93 SOUTH AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 94 REST OF MEA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
  • TABLE 95 REST OF MEA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
  • TABLE 96 REST OF MEA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 97 RAGHAVA LIFE SCIENCES PVT LTD: PRODUCT OFFERED
  • TABLE 98 ACTYLIS: PRODUCT OFFERED
  • TABLE 99 ACTYLIS: PRODUCT OFFERED
  • TABLE 100 CHIRACON GMBH: PRODUCT OFFERED
  • TABLE 101 CODEXIS, INC.: PRODUCT OFFERED
  • TABLE 102 CODEXIS, INC.: PRODUCT OFFERED
  • TABLE 103 ARKEMA S.A.: PRODUCT OFFERED
  • TABLE 104 LONZA GROUP AG: PRODUCT OFFERED
  • TABLE 105 LONZA GROUP AG: PRODUCT OFFERED
  • TABLE 106 THERMO FISHER SCIENTIFIC (PATHEON): PRODUCT OFFERED
  • TABLE 107 THERMO FISHER SCIENTIFIC (PATHEON): PRODUCT OFFERED
  • TABLE 108 CAMBREX CORPORATION: PRODUCT OFFERED
  • TABLE 109 CAMBREX CORPORATION: PRODUCT OFFERED
  • TABLE 110 CATALENT, INC.: PRODUCT OFFERED
  • TABLE 111 CATALENT, INC.: PRODUCT OFFERED
  • TABLE 112 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD: PRODUCT OFFERED
  • TABLE 113 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD: PRODUCT OFFERED

LIST OF FIGURES

  • FIGURE 1 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKETSEGMENT
  • FIGURE 2 DRIVER IMPACT ANALYSIS (2018-2035)
  • FIGURE 3 RESTRAINT IMPACT ANALYSIS (2018-2035)
  • FIGURE 4 SUPPLY CHAIN ANALYSIS
  • FIGURE 5 PORTER'S FIVE FORCES MODEL: GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET
  • FIGURE 6 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2024 (% SHARE)
  • FIGURE 7 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2024 (% SHARE)
  • FIGURE 8 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2024 (% SHARE)
  • FIGURE 9 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY REGION, 2024 (% SHARE)
  • FIGURE 10 NORTH AMERICAN MARKET: SWOT ANALYSIS
  • FIGURE 11 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE)
  • FIGURE 12 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE)
  • FIGURE 13 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE)
  • FIGURE 14 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE)
  • FIGURE 15 EUROPE MARKET: SWOT ANALYSIS
  • FIGURE 16 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE)
  • FIGURE 17 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE)
  • FIGURE 18 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE)
  • FIGURE 19 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE)
  • FIGURE 20 ASIA PACIFIC MARKET: SWOT ANALYSIS
  • FIGURE 21 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE)
  • FIGURE 22 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE)
  • FIGURE 23 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE)
  • FIGURE 24 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE)
  • FIGURE 25 SOUTH AMERICA MARKET: SWOT ANALYSIS
  • FIGURE 26 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE)
  • FIGURE 27 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE)
  • FIGURE 28 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE)
  • FIGURE 29 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE)
  • FIGURE 30 MIDDEL EAST AND AFRICA: SWOT ANALYSIS
  • FIGURE 31 MIDDEL EAST AND AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE)
  • FIGURE 32 MIDDLE EAST & AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE)
  • FIGURE 33 MIDDLE EAST & AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE)
  • FIGURE 34 MIDDLE EAST & AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE)
  • FIGURE 35 MIDDLE EAST & AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE)
  • FIGURE 36 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET: COMPETITIVE ANALSIS, 2024
  • FIGURE 37 COMPETITOR DASHBOARD: GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET
  • FIGURE 38 RAGHAVA LIFE SCIENCES PVT LTD: SWOT ANALYSIS
  • FIGURE 39 ACTYLIS: SWOT ANALYSIS
  • FIGURE 40 CHIRACON GMBH: SWOT ANALYSIS
  • FIGURE 41 CODEXIS, INC.: SWOT ANALYSIS
  • FIGURE 42 ARKEMA S.A.: SWOT ANALYSIS
  • FIGURE 43 LONZA GROUP AG: SWOT ANALYSIS
  • FIGURE 44 THERMO FISHER SCIENTIFIC (PATHEON): SWOT ANALYSIS
  • FIGURE 45 CAMBREX CORPORATION: SWOT ANALYSIS
  • FIGURE 46 CATALENT, INC: SWOT ANALYSIS
  • FIGURE 47 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD: SWOT ANALYSIS